Atossa Therapeutics, Inc. (FRA:YAG2)

Market Cap	82.45M
Revenue (ttm)	n/a
Net Income (ttm)	-25.72M
Shares Out	n/a
EPS (ttm)	-0.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	871
Open	0.6790
Previous Close	0.6640
Day's Range	0.6790 - 0.6790
52-Week Range	0.5200 - 1.2100
Beta	n/a
RSI	39.26
Earnings Date	Nov 20, 2025

About Atossa Therapeutics

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Thera...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 15
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: YAG2

Financial Performance

Financial numbers in USD